WO2023066348A1 - 一种双重拮抗剂及其用途 - Google Patents
一种双重拮抗剂及其用途 Download PDFInfo
- Publication number
- WO2023066348A1 WO2023066348A1 PCT/CN2022/126482 CN2022126482W WO2023066348A1 WO 2023066348 A1 WO2023066348 A1 WO 2023066348A1 CN 2022126482 W CN2022126482 W CN 2022126482W WO 2023066348 A1 WO2023066348 A1 WO 2023066348A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkylene
- membered
- alkyl
- alkynyl
- alkenyl
- Prior art date
Links
- 230000009977 dual effect Effects 0.000 title claims abstract description 8
- 239000005557 antagonist Substances 0.000 title claims description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 120
- 108050000824 Angiotensin II receptor Proteins 0.000 claims abstract description 11
- 102000008873 Angiotensin II receptor Human genes 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 102000010180 Endothelin receptor Human genes 0.000 claims abstract description 9
- 108050001739 Endothelin receptor Proteins 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 113
- -1 halogen substituted Chemical class 0.000 claims description 107
- 125000000217 alkyl group Chemical group 0.000 claims description 95
- 125000003342 alkenyl group Chemical group 0.000 claims description 75
- 125000000304 alkynyl group Chemical group 0.000 claims description 75
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 62
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 61
- 125000003118 aryl group Chemical group 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 32
- 125000002947 alkylene group Chemical group 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 150000002367 halogens Chemical group 0.000 claims description 22
- 125000004429 atom Chemical group 0.000 claims description 15
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 125000003003 spiro group Chemical group 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 230000008816 organ damage Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 3
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 187
- 238000006243 chemical reaction Methods 0.000 description 85
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 62
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 43
- 230000002829 reductive effect Effects 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- 239000012074 organic phase Substances 0.000 description 36
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 34
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 239000003208 petroleum Substances 0.000 description 31
- 238000004440 column chromatography Methods 0.000 description 30
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 30
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
- 239000012043 crude product Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 125000004434 sulfur atom Chemical group 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 9
- 239000012312 sodium hydride Substances 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000004430 oxygen atom Chemical group O* 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 6
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 6
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 6
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 6
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 102400000345 Angiotensin-2 Human genes 0.000 description 5
- 101800000733 Angiotensin-2 Proteins 0.000 description 5
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 5
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 5
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 229950006323 angiotensin ii Drugs 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003228 microsomal effect Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- WRFHGDPIDHPWIQ-UHFFFAOYSA-N 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O=C1N(CC=2C=C(COCC)C(=CC=2)C=2C(=CC=CC=2)S(=O)(=O)NC=2C(=C(C)ON=2)C)C(CCCC)=NC21CCCC2 WRFHGDPIDHPWIQ-UHFFFAOYSA-N 0.000 description 3
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- 102400000686 Endothelin-1 Human genes 0.000 description 3
- 101800004490 Endothelin-1 Proteins 0.000 description 3
- AKQOBHZKBDHWQI-BZEFIUHZSA-N O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O Chemical compound O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O AKQOBHZKBDHWQI-BZEFIUHZSA-N 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940127108 compound 5g Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical group C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 230000008406 drug-drug interaction Effects 0.000 description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 238000004237 preparative chromatography Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229950002009 sparsentan Drugs 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 2
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 2
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 2
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 2
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 2
- KKKJYDOHVKIIQP-UHFFFAOYSA-N 2-[4-(3-chlorobenzoyl)phenoxy]-N-pyridin-3-ylacetamide Chemical compound ClC=1C=C(C(=O)C2=CC=C(OCC(=O)NC=3C=NC=CC=3)C=C2)C=CC=1 KKKJYDOHVKIIQP-UHFFFAOYSA-N 0.000 description 2
- LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 2
- QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 2
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 2
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VFMMPHCGEFXGIP-UHFFFAOYSA-N 7,8-Benzoflavone Chemical compound O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1C1=CC=CC=C1 VFMMPHCGEFXGIP-UHFFFAOYSA-N 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125796 compound 3d Drugs 0.000 description 2
- 229940125801 compound 7f Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000004431 deuterium atom Chemical group 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 229960005127 montelukast Drugs 0.000 description 2
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 2
- JBLLRCOZJMVOAE-HSQYWUDLSA-N n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methoxy-1h-indole-2-carboxamide Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)C=1NC=2C=CC=C(C=2C=1)OC)C(=O)C=1SC2=CC=CC=C2N=1)[C@@H]1CCNC1=O JBLLRCOZJMVOAE-HSQYWUDLSA-N 0.000 description 2
- RCSBCWXPGSPJNF-UHFFFAOYSA-N n-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1C(O1)=NN=C1CCCCNC(=O)CCCC1=CC=C(C=CC=N2)C2=N1 RCSBCWXPGSPJNF-UHFFFAOYSA-N 0.000 description 2
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 2
- 229960004818 sulfaphenazole Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- DWUJDNHHQKEOPR-UHFFFAOYSA-N 2-(2-piperidin-4-ylethyl)pyridine Chemical compound C1CNCCC1CCC1=CC=CC=N1 DWUJDNHHQKEOPR-UHFFFAOYSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- VFPWGZNNRSQPBT-UHFFFAOYSA-N 2-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1Br VFPWGZNNRSQPBT-UHFFFAOYSA-N 0.000 description 1
- JOFDSYLCZIHGGO-UHFFFAOYSA-N 4-[(4-cyclohexylphenyl)methyl-[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl-methylamino]acetyl]amino]-2-hydroxybenzoic acid Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N(C)CC(=O)N(C=1C=C(O)C(C(O)=O)=CC=1)CC(C=C1)=CC=C1C1CCCCC1 JOFDSYLCZIHGGO-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DGJMHKMYSDYOFP-MRXNPFEDSA-N C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O Chemical compound C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O DGJMHKMYSDYOFP-MRXNPFEDSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- BEXZJJQVPWJPOA-VOTSOKGWSA-N [(e)-hept-2-enyl] 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxylate Chemical compound CCCC\C=C\COC(=O)C1=C(C)NC(=O)NC1C1=CC=C([N+]([O-])=O)C=C1 BEXZJJQVPWJPOA-VOTSOKGWSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- JAMFGQBENKSWOF-UHFFFAOYSA-N bromo(methoxy)methane Chemical compound COCBr JAMFGQBENKSWOF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002109 crystal growth method Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MAWOHFOSAIXURX-UHFFFAOYSA-N cyclopentylcyclopentane Chemical group C1CCCC1C1CCCC1 MAWOHFOSAIXURX-UHFFFAOYSA-N 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000002862 dinucleoside phosphate Substances 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- JHHMSRLTZAUMOJ-UHFFFAOYSA-N methanamine;oxolane Chemical compound NC.C1CCOC1 JHHMSRLTZAUMOJ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000005961 oxazepanyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a new compound with double antagonism of angiotensin II receptor and endothelin receptor and its application in preparation of medicine.
- Angiotensin II (AngII) and endothelin-1 (ET-1) are two potent endogenous vasoactive peptides thought to play roles in both the control of vascular tone and pathological tissue remodeling associated with various diseases effect.
- angiotensin II receptor antagonists have shown advantages such as strong affinity, high selectivity, oral efficacy, long half-life, and good tolerance.
- Endothelin is a potent vasoconstrictor vasoactive peptide that plays a key role in maintaining vascular homeostasis.
- endothelin receptors such as ETA, ETB1, ETB2 and ETC, etc.
- ETA is the most well-studied, and its antagonists can be used to treat hypertension, pulmonary hypertension, chronic kidney disease, etc. disease, atherosclerosis, etc.
- Dual antagonists of angiotensin II receptors and endothelin receptors can antagonize both angiotensin II receptors and ETA receptors, and have better curative effect and wider adaptability than single angiotensin II or ETA receptor antagonists.
- it is a class of drugs that can potentially be used for diseases such as high blood pressure or kidney disease.
- WO2000001389A1, CN101891735A, etc. disclose a series of angiotensin II receptor and endothelin receptor dual antagonists, it is still necessary to develop dual antagonists with better activity, higher selectivity, better water solubility, and smaller drug-drug interactions. Antagonist drugs.
- the present invention provides a compound represented by formula I, or its deuterated compound, or its stereoisomer, or its pharmaceutically acceptable salt:
- X is selected from NR X1 or CR X2 R X3 ;
- Y is selected from chemical bond, NR Y1 or CR Y2 R Y3 ;
- R Y1 is selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted -C 2 ⁇ 6 alkenyl Group, halogen substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 4 alkylene-(3 ⁇ 10 membered carbocyclyl), -C 0 ⁇ 4 alkylene-(4 ⁇ 10 membered heterocycloalkyl ), -C 0 ⁇ 4 alkylene-(6 ⁇ 10 membered aromatic ring), -C 0 ⁇ 4 alkylene-(5 ⁇ 10 membered aromatic heterocycle);
- R Y2 and R Y3 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl substituted by halogen, -C 0 ⁇ 4 alkylene-(3 ⁇ 10 membered carbocyclyl), -C 0 ⁇ 4 alkylene-(4 ⁇ 10-membered heterocycloalkyl), -C 0-4 alkylene-(6-10-membered aromatic ring), -C 0-4- membered alkylene-(5-10-membered aromatic heterocycle);
- R X1 is selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted -C 2 ⁇ 6 alkenyl Group, halogen substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 4 alkylene-(3 ⁇ 10 membered carbocyclyl), -C 0 ⁇ 4 alkylene-(4 ⁇ 10 membered heterocycloalkyl ), -C 0 ⁇ 4 alkylene-(6 ⁇ 10 membered aromatic ring), -C 0 ⁇ 4 alkylene-(5 ⁇ 10 membered aromatic heterocyclic ring); among them, alkylene, carbocyclyl, hetero Cycloalkyl, aromatic ring, aromatic heterocyclic ring can be further optionally substituted by one, two, three or four independent R X11 ;
- Each R X11 is independently selected from hydrogen, halogen, cyano, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, Halogen substituted -C 2 ⁇ 6 alkenyl, Halogen substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 4 alkylene-OR X12 , -C 0 ⁇ 4 alkylene-SR X12 , -C 0 ⁇ 4 Alkylene-NR X12 R X13 ; alternatively, two independent R X11 form together with attached atoms
- R X12 and R X13 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2 ⁇ 6 alkenyl, halogen substituted -C 2 ⁇ 6 alkynyl;
- R X2 , R X3 and the atoms directly connected together form a 6-12-membered spiro ring, a 6-12-membered spiro heterocycle, a 6-12-membered condensed ring, and a 6-12-membered condensed heterocycle; among them, the spiro ring and the spiro heterocycle , fused ring, fused heterocyclic ring can be further optionally substituted by one, two, three or four independent R X21 ;
- Each R X21 is independently selected from hydrogen, halogen, cyano, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, Halogen substituted -C 2 ⁇ 6 alkenyl, Halogen substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 4 alkylene-OR X22 , -C 0 ⁇ 4 alkylene-SR X22 , -C 0 ⁇ 4 Alkylene-NR X22 R X23 ; alternatively, two independent R X21 are formed together with the atoms to which they are directly attached
- R X22 and R X23 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2 ⁇ 6 alkenyl, halogen substituted -C 2 ⁇ 6 alkynyl;
- R 1 is selected from -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl substituted by halogen;
- R 2 is selected from -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted -C 2 ⁇ 6 alkenyl, Halogen-substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 4 alkylene-OR 21 , -C 0 ⁇ 4 alkylene-SR 21 , -C 0 ⁇ 4 alkylene-NR 21 R 22 , - C 0 ⁇ 4 alkylene-OC(O)R 21 , -C 0 ⁇ 4 alkylene-S(O) 2 R 21 , -C 0 ⁇ 4 alkylene-S(O)R 21 , -C 0-4 alkylene-S(O) 2 NR 21 R 22 , -C 0-4 alkylene-S(O)NR 21 R 22 , -C 0-4 alkylene-S(O)NR 21 R 22
- R 21 and R 22 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl substituted by halogen, -C 0 ⁇ 4 alkylene-(3 ⁇ 10 membered carbocyclyl), -C 0 ⁇ 4 alkylene-(4 ⁇ 10 membered heterocycloalkyl), -C 0 ⁇ 4 alkylene-(6 ⁇ 10 membered aromatic ring), -C 0 ⁇ 4 alkylene-(5 ⁇ 10 membered aromatic heterocyclic ring);
- R 3 and R 4 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl substituted by halogen, -C 0 ⁇ 4 alkylene-(3 ⁇ 10 membered carbocyclyl), -C 0 ⁇ 4 alkylene-(4 ⁇ 10 membered heterocycloalkyl), -C 0 ⁇ 4 alkylene-(6 ⁇ 10 membered aromatic ring), -C 0 ⁇ 4 alkylene-(5 ⁇ 10 membered aromatic heterocyclic ring); among them, alkylene, Carbocyclyl, heterocycloalkyl, aromatic ring, aromatic heterocyclic ring can be further optionally substituted by one, two, three or four independent R31 ;
- Each R 31 is independently selected from hydrogen, halogen, cyano, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, Halogen substituted -C 2 ⁇ 6 alkenyl, Halogen substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 4 alkylene-OR 32 , -C 0 ⁇ 4 alkylene-SR 32 , -C 0 ⁇ 4 alkylene-NR 32 R 33 , -C 0 ⁇ 4 alkylene-OC(O)R 32 , -C 0 ⁇ 4 alkylene-S(O) 2 R 32 , -C 0 ⁇ 4 alkylene -S(O)R 32 , -C 0 ⁇ 4 alkylene-S(O) 2 NR 32 R 33 , -C 0 ⁇ 4 alkylene-S(O)NR 32 R 33 , -C 0 ⁇ 4 al
- R 32 and R 33 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2-6 alkenyl, halogen-substituted -C 2-6 alkynyl.
- R 1 is selected from n-butyl.
- R 2 is selected from -C 1 ⁇ 2 alkylene-OR 21 , -C 1 ⁇ 2 alkylene-SR 21 , -C 1 ⁇ 2 alkylene-NR 21 R 22 , -C 1 ⁇ 2 alkylene -OC(O)R 21 , -C 1 ⁇ 2 alkylene-S(O) 2 R 21 , -C 1 ⁇ 2 alkylene-S(O)R 21 , -C 1 ⁇ 2 alkylene- S(O) 2 NR 21 R 22 , -C 1 ⁇ 2 alkylene-S(O)NR 21 R 22 , -C 1 ⁇ 2 alkylene-C(O)R 21 , -C 1 ⁇ 2 alkylene Alkyl-C(O)OR 21 , -C 1 ⁇ 2 alkylene-C(O)NR 21 R 22 , -C 1 ⁇ 2 alkylene-NR 21 C(O)R 22 , -C 1 ⁇ 2 alkylene-NR 21 S(O) 2 R 22 , -C 1 ⁇ 2 al
- R 21 and R 22 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl substituted by halogen, -C 0 ⁇ 2 alkylene-(3 ⁇ 10 membered carbocyclyl), -C 0 ⁇ 2 alkylene-(4 ⁇ 10 membered heterocycloalkyl).
- R2 is selected from
- R 21 and R 22 are independently selected from hydrogen, -C 1-6 alkyl, halogen-substituted -C 1-6 alkyl, -C 0-2 alkylene-(3-6 membered carbocyclyl).
- R2 is selected from
- R 3 is selected from -C 0 ⁇ 2 alkylene-(3 ⁇ 10 membered carbocyclyl), -C 0 ⁇ 2 alkylene-(4 ⁇ 10 membered heterocycloalkyl), -C 0 ⁇ 2 alkylene Base-(6-10 membered aromatic ring), -C 0-2 alkylene-(5-10 membered aromatic heterocyclic ring); among them, alkylene, carbocyclyl, heterocycloalkyl, aromatic ring, aromatic hetero The ring can be further optionally substituted by one, two, three or four independent R 31 ;
- Each R 31 is independently selected from hydrogen, halogen, cyano, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, Halogen substituted -C 2 ⁇ 6 alkenyl, halogen substituted -C 2 ⁇ 6 alkynyl; or, two independent R 31 are formed together with the atoms directly connected to them
- R 4 is selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted -C 2 ⁇ 6 alkenyl Group, -C 2 ⁇ 6 alkynyl substituted by halogen.
- R3 is selected from 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, 6-membered carbocyclyl, 7-membered carbocyclyl, 8-membered carbocyclyl, 9-membered carbocyclyl, 10-membered carbocyclyl group, 4-membered heterocycloalkyl, 5-membered heterocycloalkyl, 6-membered heterocycloalkyl, 7-membered heterocycloalkyl, 8-membered heterocycloalkyl, 9-membered heterocycloalkyl, 10-membered heterocycloalkyl , 6-membered aromatic ring, 10-membered aromatic ring, 5-membered aromatic heterocycle, 6-membered aromatic heterocycle, 7-membered aromatic heterocycle, 8-membered aromatic heterocycle, 9-membered aromatic heterocycle, 8-membered aromatic heterocycle; among them, carbon Cyclic group, heterocycloalkyl,
- R 4 is selected from hydrogen, -C 1-6 alkyl.
- R3 is selected from Wherein, the ring selected by R3 can be further optionally replaced by one, two, three or four independent R31 .
- R3 is selected from
- X is selected from NR X1 ;
- R X1 is selected from -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted -C 2 ⁇ 6 alkenyl, Halogen substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 2 alkyl-(3 ⁇ 10 membered carbocyclyl), -C 0 ⁇ 2 alkyl-(4 ⁇ 10 membered heterocycloalkyl), -C 0-2 alkyl-(6-10 membered aromatic ring), -C 0-2 alkyl-(5-10 membered aromatic heterocycle).
- R X1 is selected from -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, 6-membered carbocycle Base, 7-membered carbocyclyl, 8-membered carbocyclyl, 4-membered heterocycloalkyl, 5-membered heterocycloalkyl, 6-membered heterocycloalkyl, 7-membered heterocycloalkyl, 8-membered heterocycloalkyl, benzene Ring, 5-membered aromatic heterocycle, 6-membered aromatic heterocycle.
- R X1 selected from
- n1 and m2 are independently selected from 0, 1, 2 or 3;
- n3 is selected from 1, 2, 3, 4 or 5.
- n1 and n2 are independently selected from 0, 1, 2 or 3;
- n3 is selected from 1, 2, 3, 4 or 5.
- the compound is specifically:
- the present invention also provides any one of the above-mentioned compounds, or their deuterated compounds, or their stereoisomers, or their pharmaceutically acceptable salts in the preparation of angiotensin II receptor and endothelin receptor dual antagonist drugs the use of.
- the present invention also provides any one of the above-mentioned compounds, or their deuterated compounds, or their stereoisomers, or their pharmaceutically acceptable salts for use in the treatment of cardiovascular and cerebrovascular diseases including hypertension, and kidney diseases. Use in medicine for diseases associated with diabetes-related organ damage.
- the present invention also provides a pharmaceutical composition, which includes preparations prepared from any of the above-mentioned compounds, or deuterated compounds thereof, or stereoisomers thereof, or pharmaceutically acceptable salts thereof.
- the above pharmaceutical composition further includes pharmaceutically acceptable carriers, adjuvants and vehicles.
- the present invention also provides a method for treating diseases related to angiotensin II receptors and endothelin receptors, the method comprising administering an effective amount of any one of the above compounds of the present invention, or its deuterated Substitute compound, or stereoisomer thereof, or pharmaceutically acceptable salt thereof, or any above-mentioned composition;
- said disease includes cardiovascular and cerebrovascular diseases including hypertension, kidney disease and diabetes-related organ damage related diseases.
- the present invention also provides a compound represented by formula IIIa or formula IIIb, or a deuterated compound thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
- R1 is selected from -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl , halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted -C 2 ⁇ 6 alkenyl, halogen substituted -C 2 ⁇ 6 alkynyl, preferably from n-butyl;
- m1, m2 are independently selected from 0, 1 , 2 or 3;
- m3 is selected from 1, 2, 3, 4 or 5;
- n1, n2 are independently selected from 0, 1, 2 or 3;
- n3 is selected from 1, 2, 3, 4 or 5.
- the compound shown in the preferred formula IIIa or formula IIIb is selected from
- the compounds and derivatives provided in the present invention may be named according to the IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracts Service, Columbus, OH) nomenclature system.
- substitution means that the hydrogen atom in the molecule is replaced by other different atoms or groups; or the lone pair of electrons of atoms in the molecule is replaced by other atoms or groups, for example, the lone pair of electrons on the S atom can be replaced by O atomic substitution formation
- C a-b alkyl indicates any alkyl group containing "a" to "b" carbon atoms.
- C 1-6 alkyl refers to an alkyl group containing 1-6 carbon atoms.
- Alkyl means a saturated hydrocarbon chain having the indicated number of member atoms. Alkyl groups can be straight or branched. Representative branched alkyl groups have one, two or three branches. Alkyl groups may be optionally substituted with one or more substituents as defined herein. Alkyl groups include methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl and tert-butyl), pentyl (n-pentyl, isopentyl and neopentyl base) and hexyl. Alkyl groups may also be part of other groups such as -O(C 1-6 alkyl).
- Alkylene means a divalent saturated aliphatic hydrocarbon group having the indicated number of member atoms.
- C a ⁇ b alkylene refers to an alkylene group having a to b carbon atoms.
- Alkylene groups include branched and straight chain hydrocarbyl groups.
- the term "propylene” can be exemplified by the following structures:
- the term "dimethylbutylene” can be exemplified, for example, by any of the following structures:
- the -C 0 to 4 alkylene in the present invention can be C 0 alkylene, C 1 alkylene (such as -CH 2 -), C 2 alkylene (such as -CH 2 CH 2 -, etc.), C 3 Alkylene or C 4 alkylene;
- C 0 alkylene means that the group here does not exist, and is connected in the form of a chemical bond, such as AC 0 alkylene-B means AB, that is, the A group and The B groups are connected directly by chemical bonds.
- the "carbocyclyl” mentioned in the present invention refers to a saturated or non-aromatic partially saturated group with a single ring or multiple rings (fused, bridged, spiro) having multiple carbon atoms and no ring heteroatoms. cyclic group.
- the term "carbocyclyl” includes cycloalkenyl groups such as cyclohexenyl. Examples of monocarbocyclyl groups include, for example, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclooctyl, cyclopentenyl and cyclohexenyl.
- Examples of carbocyclyl groups of condensed carbocyclyl systems include bicyclohexyl, bicyclopentyl, bicyclooctyl, etc., and two such bicycloalkyl polycyclic structures are exemplified and named below: Bicyclohexyl and Bicyclohexyl.
- Examples of carbocyclyl groups of bridged carbocyclyl systems include Adamantyl, etc.
- Examples of carbocyclyl groups for spirocarbocyclyl systems include wait.
- Carbocyclyl also includes the case of a partially saturated cyclic group formed by the fusion of an aromatic ring and a non-aromatic ring, and the point of attachment may be at a non-aromatic carbon atom or an aromatic carbon atom, examples include 1,2, 3,4-tetrahydronaphthalen-5-yl, 5,6,7,8-tetrahydronaphthalen-5-yl.
- saturated in the present invention means that the groups or molecules contain carbon-carbon double bonds, carbon-carbon triple bonds, carbon-oxygen double bonds, carbon-sulfur double bonds, carbon-nitrogen triple bonds, and the like.
- Cab alkenyl refers to an alkenyl group having a to b carbon atoms and is intended to include, for example, ethenyl, propenyl, isopropenyl, 1,3-butadienyl, and the like.
- Alkynyl means a linear or branched monovalent hydrocarbon radical containing at least one triple bond.
- alkynyl is also intended to include those hydrocarbyl groups having one triple bond and one double bond.
- C alkynyl is intended to include ethynyl, propynyl, and the like.
- heterocycloalkyl refers to a saturated ring or a non-aromatic partially saturated ring with a single ring or multiple rings (fused, bridged, spiro) containing at least one heteroatom; wherein A hetero atom refers to a nitrogen atom, an oxygen atom, a sulfur atom, and the like.
- a hetero atom refers to a nitrogen atom, an oxygen atom, a sulfur atom, and the like.
- heterocycloalkyl groups for monoheterocycloalkyl systems are oxetanyl, azetidinyl, pyrrolidinyl, 2-oxo-pyrrolidin-3-yl, tetrahydrofuranyl, tetrahydro- Thienyl, pyrazolidinyl, imidazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1- Dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl or oxazepanyl, etc.
- heterocycloalkyl groups for fused heterocycloalkyl systems include 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl, 8-oxa-3-aza-bicyclo[3.2 .1] Octyl, 9-aza-bicyclo[3.3.1]nonyl, etc.
- heterocycloalkyl groups for bridged heterocycloalkyl systems include wait.
- heterocycloalkyl groups for spiroheterocycloalkyl systems include wait.
- partially saturated heterocycloalkyl are dihydrofuranyl, imidazolinyl, tetrahydro-pyridyl or dihydropyranyl and the like.
- heterocycloalkyl also includes the case where an aromatic ring containing at least one heteroatom is fused with a non-aromatic ring to form a partially saturated cyclic group, and the point of attachment may be at a non-aromatic carbon atom, an aromatic carbon atom or heteroatoms, examples include
- aromatic ring refers to an aromatic hydrocarbon group having multiple carbon atoms.
- Aryl groups are typically monocyclic, bicyclic or tricyclic aryl groups having multiple carbon atoms.
- aryl refers to an aromatic substituent which may be a single aromatic ring or multiple aromatic rings fused together. Non-limiting examples include phenyl, naphthyl or tetrahydronaphthyl.
- heteromatic ring refers to an aromatic unsaturated ring containing at least one heteroatom; wherein the heteroatom refers to nitrogen atom, oxygen atom, sulfur atom and the like.
- Aromatic monocyclic or bicyclic hydrocarbons usually containing multiple ring atoms, wherein one or more ring atoms are selected from O, N, S heteroatoms. There are preferably one to three heteroatoms.
- Heterocyclic aryl represents for example: pyridyl, indolyl, quinoxalinyl, quinolinyl, isoquinolyl, benzothienyl, benzofuryl, benzothienyl, benzopyranyl, benzene Thiopyranyl, furyl, pyrrolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, oxadiazolyl, benzimidazole benzothiazolyl, benzoxazolyl.
- halogen refers to fluorine, chlorine, bromine or iodine.
- halogen-substituted alkyl in the present invention means that one or more hydrogen atoms in the alkyl group are replaced by halogen; for example, the halogen-substituted C1 ⁇ 4 alkyl means that the hydrogen atom is replaced by one or more halogen atoms
- oxygen atom in "-C(O)R", “-S(O) 2 R” and the like described in the present invention is connected to a carbon atom or a sulfur atom by a double bond.
- the oxygen atom in "-C(O)R", “-S(O) 2 R” and the like described in the present invention is connected with a carbon atom or a sulfur atom with a double bond, and the R group is connected with an oxygen atom or a sulfur atom Connected by a single bond;
- another example "-S(O)(NH)R” means that the oxygen atom and nitrogen atom are connected to the sulfur atom by a double bond, and the R group is connected to the sulfur atom by a single bond.
- “Chemical bond” in the description of the present invention refers to a single bond, such as When Y is selected from chemical bonds, the benzene ring and the sulfur atom of the sulfonyl group are directly linked by a single bond.
- group of the present invention is used to represent a single stereoconfiguration in a chemical structure; for example Indicates that the cyclopropane moiety has a single stereoconfiguration and the absolute configuration is indeterminate.
- the "deuterated compound” of the present invention means that one or more hydrogen atoms in a molecule or group are replaced by deuterium atoms, wherein the proportion of deuterium atoms is greater than the abundance of deuterium in nature.
- pharmaceutically acceptable means that a certain carrier, carrier, diluent, excipient, and/or formed salt are generally chemically or physically compatible with other ingredients that constitute a pharmaceutical dosage form, and are physiologically compatible Compatible with receptors.
- salts and “pharmaceutically acceptable salt” refer to the above-mentioned compounds or their stereoisomers, acidic and/or basic salts formed with inorganic and/or organic acids and bases, and also include zwitterionic salts ( Inner salts), also include quaternary ammonium salts, such as alkyl ammonium salts. These salts may be obtained directly in the final isolation and purification of the compounds. It can also be obtained by mixing the above-mentioned compound, or its stereoisomer, with a certain amount of acid or base as appropriate (for example, equivalent). These salts may form precipitates in solution and be collected by filtration, or may be recovered after evaporation of the solvent, or may be obtained by freeze-drying after reaction in an aqueous medium.
- one or more compounds of the invention may be used in combination with each other.
- the compound of the present invention may be used in combination with any other active agents for the preparation of drugs or pharmaceutical compositions for regulating cell functions or treating diseases. If a group of compounds is used, the compounds may be administered to the subject simultaneously, separately or sequentially.
- Figure 1 is a schematic diagram of the three-dimensional structure of the compound of Example 3 of the present invention obtained by X-ray single crystal diffraction analysis method.
- NMR nuclear magnetic resonance
- MS mass spectroscopy
- LC-MS Shimadzu LC-MS 2020 (ESI)).
- HPLC measurement used a Shimadzu high pressure liquid chromatograph (Shimadzu LC-20A).
- MPLC Medium Pressure Preparative Chromatography
- Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates are used for thin-layer chromatography silica gel plates, and the specifications of thin-layer chromatography separation and purification products are 0.4mm to 0.5mm.
- Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
- the known starting materials of the present invention can be adopted or synthesized according to methods known in the art, or can be purchased from companies such as Anaiji Chemical, Chengdu Kelong Chemical, Shaoyuan Chemical Technology, and Bailingwei Technology.
- the reaction is carried out under a nitrogen atmosphere.
- the solution refers to an aqueous solution.
- the temperature of the reaction is room temperature.
- M is moles per liter.
- DIBAL-H diisobutylaluminum hydride
- DPPA diphenylphosphoryl azide
- DMF dimethylformamide
- compound 1e 500 mg, 1.18 mmol was dissolved in a mixed solution of toluene (2 mL) and ethanol (1 mL), then tetrakis(triphenylphosphine) palladium (137 mg, 0.118 mmol), sodium carbonate ( 377 mg, 3.56 mmol). The temperature of the reaction system was raised to 85° C. and reacted for 3 hours.
- compound 1k 820 mg, crude product obtained in the previous step was dissolved in methanol (5 mL), and potassium hydroxide (172 mg, 3.07 mmol) and hydrogen peroxide (30%, 2 mL, 4.91 mmol) were added. After the reaction system was reacted at 50°C for 30 minutes, it was cooled to room temperature and potassium hydroxide (689mg, 12.28mmol) was added again, and the reaction system was heated to 70°C for 2 hours. After the reaction was detected by LC-MS and TLC, solid ammonium chloride (100 mg) was added to the reaction system for neutralization. Concentrate under reduced pressure and extract with ethyl acetate (10 mL).
- compound 2b 350mg, 3.22mmol was dissolved in 1ml of water, hydrochloric acid solution (0.5N, 0.35mL) was added dropwise into the system, and after stirring for 5 minutes, compound 2a (460mg, 3.53mmol) was Aqueous solution (1 mL) was dripped into the system. After stirring for 4 hours, ethanol was added to the reaction system until the system was clear, and the reaction solution was frozen at 4° C. for 16 hours.
- diiodomethane (24.5g, 91.5mmol) was carefully dropped into a dichloromethane solution of diethylzinc (166mL, 1M, 166mmol), stirred for 30 minutes, compound 3a (7.0g, 83.3mmol) was added and Continue to react for 3 hours. After the reaction was monitored by TLC, saturated aqueous ammonium chloride (100 mL) was added to quench the reaction, the system was extracted with dichloromethane (200 mL*2), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the crude compound 3e (610 mg) was dissolved in methanol (6 mL), and potassium hydroxide (332 mg, 5.92 mmol) and 30% hydrogen peroxide (1.5 mL) were added.
- the reaction system was reacted at 50° C. for 30 minutes, cooled to room temperature and potassium hydroxide (332 mg, 5.92 mmol) was added again, and the temperature of the reaction system was raised to 70° C. for 2 hours.
- solid ammonium chloride (1.2 g) was added to the reaction system and stirred, diluted with methanol and then concentrated.
- Example 3 Single crystal growth method of final product 3: Weigh 20 mg of solid, place it in an ampoule containing a mixed solution of 1 ml of ethyl acetate and 2 ml of n-hexane, put cotton wool on the mouth of the bottle to slow down the volatilization rate. The solvent was left to evaporate at room temperature, and crystals were obtained after 2 days.
- the experimental parameters and results obtained by X-ray single crystal diffraction analysis are as follows; the analyzed configuration of compound 3 is shown in Figure 1, which is consistent with the final product 3 in Example 3.
- compound 3f-1 (24.0mg, 0.12mmol) was dissolved in anhydrous N,N-dimethylformamide (1mL), sodium hydride (60%, 10.6mg, 0.26mmol) was added, and stirred for 30 Minutes later, a solution of compound 5g (70mg, 0.12mmol) in N,N-dimethylformamide (0.5mL) was added to the system. Stir at room temperature for 3 hours. After the completion of the reaction monitored by LC-MS, the system was poured into saturated ammonium chloride (10 mL), extracted with ethyl acetate (20 mL), and the separated organic phase was washed with saturated brine (10 mL). Dry over sodium sulfate and distill under reduced pressure.
- compound 3f-2 (26.0mg, 0.13mmol) was dissolved in anhydrous N,N-dimethylformamide (1.2mL), sodium hydride (60%, 11.2mg, 0.28mmol) was added, and stirred After 30 minutes, a solution of compound 5g (75 mg, 0.12 mmol) in N,N-dimethylformamide (0.7 mL) was added to the system. Stir at room temperature for 3 hours. After the completion of the reaction monitored by LC-MS, the system was poured into saturated ammonium chloride (10 mL), extracted with ethyl acetate (20 mL), and the separated organic phase was washed with saturated brine (10 mL). Dry over sodium sulfate and distill under reduced pressure.
- compound 7d (1.3g, 3.70mmol) was dissolved in N,N-dimethylformamide (10mL), sodium hydride (60%, 171mg, 4.28mmol) was added in portions, and after stirring for 5 minutes Raised to room temperature for 30 minutes. Then the system was moved to -15°C, bromomethyl methyl ether (600mg, 4.80mmol) was added dropwise, stirred for 5 minutes, and then the temperature was raised naturally for 30 minutes.
- compound 7e 300mg, 0.76mmol
- compound 7a (220mg, 0.76mmol)
- tetrakistriphenylphosphine palladium 114mg, 0.099mmol
- sodium carbonate 402mg, 3.79mmol
- the system was reacted at 85°C for 2 hours. After the completion of the reaction was detected by LC-MS, it was filtered through diatomaceous earth and concentrated under reduced pressure.
- compound 3f-1 (25.0 mg, 0.12 mmol) was dissolved in anhydrous N, N-dimethylformamide (2 mL), added sodium hydride (60%, 5.34 mg, 0.13 mmol), and stirred After 5 minutes, it was raised to room temperature and stirred for 30 minutes, then the system was moved to an ice bath, and a solution of compound 7h (55mg, 0.10mmol) in N,N-dimethylformamide (2mL) was slowly added dropwise to the reaction, After 5 minutes, it was raised to room temperature and reacted for 1 hour.
- Test materials a) cell line: AT1/HEK293; b) vehicle: F12, Invitrogen (Cat# 11765-047); FBS, Corning (Cat# 35-076-CV); Geneticin, Invitrogen (Cat# 10131); c ) Reagent: Fluo-4 Direct, (Invitrogen, Cat# F10471); d) Instrument: 384 well Poly-D-Lysine protein coating plate, Greiner #781946; Vi-cell XR Cell Viability Analyzer, Beckman Coulter; Incubator, Thermo;
- agonist angiotensin II
- antagonist Lisartan
- compound plates antagonist and test compound were serially diluted 1:4 with DMSO to obtain 10 concentration points. Then transfer 900 nL of compound solution to the master plate and add 30 ⁇ L of assay buffer solution.
- Table 1 (IC 50 of AT1 activity: + represents 100nM to 1 ⁇ M, ++ represents 10nM to 100nM, +++ represents 1nM to 10nM, and the specific activities are shown in the third column of Table 1)
- Test materials a) Cell line: ETa/HEK293; b) Medium: DMEM, Invitrogen (Cat# 11960); Geneticin, Invitrogen (Cat# 10131); c) Reagent: Fluo-4 Direct, (Invitrogen, Cat# F10471) ; d) Instruments: 384 well Poly-D-Lysine protein coating plate, Greiner #781946; Vi-cell XR Cell Viability Analyzer, Beckman Coulter; Incubator, Thermo.
- endothelin factor endothelin-1, ET-1
- the agonist was diluted from 50 ⁇ M to 15 ⁇ M with the buffer used in the test.
- antagonist and test compound were serially diluted with DMSO at a ratio of 1:4 to obtain 10 concentration points. Then transfer 900 nL of compound to the master plate, and add 30 ⁇ L of assay buffer.
- Table 2 (ETa activity IC 50 : + represents 100nM to 1 ⁇ M, ++ represents 10nM to 100nM, +++ represents 1nM to 10nM, and the specific activities are shown in the third column of Table 2)
- the detection is based on high-performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition Four General Rules 0512):
- Test Example 4 Inhibition of Human Liver Microsomal Cytochrome P450 Isoenzyme (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) Activity
- a total of 6 specific probe substrates of 6 isoenzymes of CYP were naphthoflavone ( ⁇ -Naphthoflavone, CYP1A2), sulfaphenazole (Sulphaphenazole, CYP2C9), ticlopidine (Ticlopidine, CYP2C19), quinine Quinidine (CYP2D6), ketoconazole (CYP3A4) and Montelukast (Montelukast, CYP2C8) were incubated with recombinant liver drug enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP2C8 and test compounds respectively, and smoke Amide adenine dinucleoside phosphate (NADP+), D-glucose-6-phosphate (G6P) and glucose-6-phosphate dehydrogenase (G6DHP) start the reaction, after the reaction is completed by fluor
- the compound of Example 7 has no risk of inhibiting the activities of human liver microsomal cytochrome P450 isozymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP2C8.
- Example 3 The above data predict that the clinical use of the compounds of Example 3 and Example 7 has a lower risk of DDI (drug-drug interaction).
- mice SD rats, 6-8 weeks old. Six animals were used for each example compound.
- Drug solution preparation the compounds of the test examples were prepared into 1 mg/mL solutions.
- the solution system is 5% DMSO+20% Solutol HS15+75% (20% HP- ⁇ -CD aqueous solution)
- Dosing grouping the first group of oral gavage administration (PO, 3 SD rats, 10mg/kg, fasting overnight before administration, feeding 4 hours after administration); the second group of foot dorsal intravenous injection ( IV, 3 SD rats, 1 mg/kg, free to eat).
- PO oral gavage administration
- IV foot dorsal intravenous injection
- Blood collection time and processing method blood was collected from the jugular vein at 0.083 (intravenous injection group only), 0.25, 0.5, 1, 2, 4, 8 and 24 hours, a total of 7 to 8 time points. Blood samples were centrifuged (2000g, 4°C, 5 minutes) to obtain plasma. Samples were stored at -70°C until analysis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
化合物名称 | IC 50(nM) | IC 50(nM) |
实施例1 | +++ | 2.90nM |
实施例2 | +++ | 6.14nM |
实施例3 | +++ | 1.97nM |
实施例4 | +++ | 4.78nM |
实施例5 | ++ | 26.82nM |
实施例6 | + | 257.6nM |
实施例7 | +++ | 3.55nM |
Sparsentan | +++ | 9.79nM |
Losartan | +++ | 1.86nM |
化合物名称 | IC 50(nM) | IC 50(nM) |
实施例1 | ++ | 24.60nM |
实施例2 | ++ | 23.55nM |
实施例3 | ++ | 10.53nM |
实施例4 | + | 131.60nM |
实施例5 | ++ | 14.83nM |
实施例6 | ++ | 17.58nM |
实施例7 | ++ | 24.29nM |
Sparsentan | ++ | 80.81nM |
BQ123 | +++ | 2.56nM |
Claims (20)
- 式I所示的化合物、或其氘代化合物、或其立体异构体、或其药学上可接受的盐:其中,X选自NR X1或CR X2R X3;Y选自化学键、NR Y1或CR Y2R Y3;R Y1选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-(3~10元碳环基)、-C 0~4亚烷基-(4~10元杂环烷基)、-C 0~4亚烷基-(6~10元芳环)、-C 0~4亚烷基-(5~10元芳杂环);R Y2、R Y3分别独立地选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-(3~10元碳环基)、-C 0~4亚烷基-(4~10元杂环烷基)、-C 0~4亚烷基-(6~10元芳环)、-C 0~4亚烷基-(5~10元芳杂环);R X1选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-(3~10元碳环基)、-C 0~4亚烷基-(4~10元杂环烷基)、-C 0~4亚烷基-(6~10元芳环)、-C 0~4亚烷基-(5~10元芳杂环);其中,亚烷基、碳环基、杂环烷基、芳环、芳杂环可进一步任选被一个、两个、三个或四个独立的R X11取代;每个R X11分别独立选自氢、卤素、氰基、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR X12、-C 0~4亚烷基-SR X12、-C 0~4亚烷基-NR X12R X13;或者,两个独立的R X11与其直接相连的原子一起形成R X12、R X13分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基;R X2、R X3与其直接相连的原子一起形成6~12元螺环、6~12元螺杂环、6~12元稠环、 6~12元稠杂环;其中,螺环、螺杂环、稠环、稠杂环可进一步任选被一个、两个、三个或四个独立的R X21取代;每个R X21分别独立选自氢、卤素、氰基、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR X22、-C 0~4亚烷基-SR X22、-C 0~4亚烷基-NR X22R X23;或者,两个独立的R X21与其直接相连的原子一起形成R X22、R X23分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基;R 1选自-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基;R 2选自-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR 21、-C 0~4亚烷基-SR 21、-C 0~4亚烷基-NR 21R 22、-C 0~4亚烷基-OC(O)R 21、-C 0~4亚烷基-S(O) 2R 21、-C 0~4亚烷基-S(O)R 21、-C 0~4亚烷基-S(O) 2NR 21R 22、-C 0~4亚烷基-S(O)NR 21R 22、-C 0~4亚烷基-C(O)R 21、-C 0~4亚烷基-C(O)OR 21、-C 0~4亚烷基-C(O)NR 21R 22、-C 0~4亚烷基-NR 21C(O)R 22、-C 0~4亚烷基-NR 21S(O) 2R 22、-C 0~4亚烷基-NR 21S(O)R 22、-C 0~4亚烷基-(3~10元碳环基)、-C 0~4亚烷基-(4~10元杂环烷基)、-C 0~4亚烷基-(6~10元芳环)、-C 0~4亚烷基-(5~10元芳杂环);R 21、R 22分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-(3~10元碳环基)、-C 0~4亚烷基-(4~10元杂环烷基)、-C 0~4亚烷基-(6~10元芳环)、-C 0~4亚烷基-(5~10元芳杂环);R 3、R 4分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-(3~10元碳环基)、-C 0~4亚烷基-(4~10元杂环烷基)、-C 0~4亚烷基-(6~10元芳环)、-C 0~4亚烷基-(5~10元芳杂环);其中,所述的亚烷基、碳环基、杂环烷基、芳环、芳杂环可进一步任选被一个、两个、三个或四个独立的R 31取代;每个R 31分别独立选自氢、卤素、氰基、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR 32、-C 0~4亚烷基-SR 32、-C 0~4亚烷基-NR 32R 33、-C 0~4亚烷基-OC(O)R 32、-C 0~4亚烷基-S(O) 2R 32、-C 0~4亚烷基-S(O)R 32、-C 0~4亚烷基-S(O) 2NR 32R 33、-C 0~4亚烷基-S(O)NR 32R 33、-C 0~4亚烷基 -C(O)R 32、-C 0~4亚烷基-C(O)OR 32、-C 0~4亚烷基-C(O)NR 32R 33、-C 0~4亚烷基-NR 32C(O)R 33、-C 0~4亚烷基-NR 32S(O) 2R 33、-C 0~4亚烷基-NR 32S(O)R 33、-C 0~4亚烷基-(3~10元碳环基)、-C 0~4亚烷基-(4~10元杂环烷基)、-C 0~4亚烷基-(6~10元芳环)、-C 0~4亚烷基-(5~10元芳杂环);或者,两个独立的R 31与其直接相连的原子一起形成R 32、R 33分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基。
- 根据权利要求1所述的化合物、或其氘代化合物、或其立体异构体、或其药学上可接受的盐,其特征在于:R 1选自正丁基。
- 根据权利要求1所述的化合物、或其氘代化合物、或其立体异构体、或其药学上可接受的盐,其特征在于:R 2选自-C 1~2亚烷基-OR 21、-C 1~2亚烷基-SR 21、-C 1~2亚烷基-NR 21R 22、-C 1~2亚烷基-OC(O)R 21、-C 1~2亚烷基-S(O) 2R 21、-C 1~2亚烷基-S(O)R 21、-C 1~2亚烷基-S(O) 2NR 21R 22、-C 1~2亚烷基-S(O)NR 21R 22、-C 1~2亚烷基-C(O)R 21、-C 1~2亚烷基-C(O)OR 21、-C 1~2亚烷基-C(O)NR 21R 22、-C 1~2亚烷基-NR 21C(O)R 22、-C 1~2亚烷基-NR 21S(O) 2R 22、-C 1~2亚烷基-NR 21S(O)R 22;R 21、R 22分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~2亚烷基-(3~10元碳环基)、-C 0~2亚烷基-(4~10元杂环烷基)。
- 根据权利要求1所述的化合物、或其氘代化合物、或其立体异构体、或其药学上可接受的盐,其特征在于:R 3选自-C 0~2亚烷基-(3~10元碳环基)、-C 0~2亚烷基-(4~10元杂环烷基)、-C 0~2亚烷基-(6~10元芳环)、-C 0~2亚烷基-(5~10元芳杂环);其中,亚烷基、碳环基、杂环烷基、芳环、芳杂环可进一步任选被一个、两个、三个或四个独立的R 31取代;每个R 31分别独立选自氢、卤素、氰基、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基;或者,两个独立的R 31与其直接相连的原子一起形成R 4选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基。
- 根据权利要求6所述的化合物、或其氘代化合物、或其立体异构体、或其药学上可接受的盐,其特征在于:R 3选自3元碳环基、4元碳环基、5元碳环基、6元碳环基、7元碳环基、8元碳环基、9元碳环基、10元碳环基、4元杂环烷基、5元杂环烷基、6元杂环烷基、7元杂环烷基、8元杂环烷基、9元杂环烷基、10元杂环烷基、6元芳环、10元芳环、5元芳杂环、6元芳杂环、7元芳杂环、8元芳杂环、9元芳杂环、8元芳杂环;其中,碳环基、杂环烷基、芳环、芳杂环可进一步任选被一个、两个、三个或四个独立的R 31取代;R 4选自氢、-C 1~6烷基。
- 根据权利要求1~9任一项所述的化合物、或其氘代化合物、或其立体异构体、或其药学上可接受的盐,其特征在于:X选自NR X1;R X1选自-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~2烷基-(3~10元碳环基)、-C 0~2烷基-(4~10元杂环烷基)、-C 0~2烷基-(6~10元芳环)、-C 0~2烷基-(5~10元芳杂环)。
- 根据权利要求10所述的化合物、或其氘代化合物、或其立体异构体、或其药学上可接受的盐,其特征在于:R X1选自-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、3元碳环基、4元碳环基、5元碳环基、6元碳环基、7元碳环基、8元碳环基、4元杂环烷基、5元杂环烷基、6元杂环烷基、7元杂环烷基、8元杂环烷基、苯环、5元芳杂环、6元芳杂环。
- 权利要求1~14任一项所述的化合物、或其氘代化合物、或其立体异构体、或其药学上可接受的盐在制备血管紧张素II受体及内皮素受体双重拮抗剂药物中的用途。
- 权利要求1~14任一项所述的化合物、或其氘代化合物、或其立体异构体、或其药学上可接受的盐在制备用于治疗包括高血压在内的心脑血管疾病、肾脏疾病和糖尿病相关的器官损害有关的疾病的药物中的用途。
- 一种药物组合物,包括权利要求1~14任一项所述的化合物、或其氘代化合物、 或其立体异构体、或其药学上可接受的盐制备而成的制剂。
- 根据权利要求17所述的药物组合物,其进一步包括药学上可接受的载体、辅料、媒介物。
- 一种治疗血管紧张素II受体及内皮素受体有关病症的方法,所述方法包括向有需要的受试者施用有效量的权利要求1~14任一项所述的化合物、或其氘代化合物、或其立体异构体、或其药学上可接受的盐或者权利要求17-18任一项所述的组合物;优选的所述疾病包括高血压在内的心脑血管疾病、肾脏疾病和糖尿病相关的器官损害有关的疾病。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3235437A CA3235437A1 (en) | 2021-10-21 | 2022-10-20 | Dual antagonist and use thereof |
CN202280070467.6A CN118119617A (zh) | 2021-10-21 | 2022-10-20 | 一种双重拮抗剂及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111228856 | 2021-10-21 | ||
CN202111228856.0 | 2021-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023066348A1 true WO2023066348A1 (zh) | 2023-04-27 |
Family
ID=86057954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/126482 WO2023066348A1 (zh) | 2021-10-21 | 2022-10-20 | 一种双重拮抗剂及其用途 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN118119617A (zh) |
CA (1) | CA3235437A1 (zh) |
WO (1) | WO2023066348A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115745983A (zh) * | 2022-11-23 | 2023-03-07 | 深圳信立泰药业股份有限公司 | 一种血管紧张肽和内皮肽受体拮抗剂及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993001177A1 (en) * | 1991-07-03 | 1993-01-21 | Merck & Co., Inc. | Substituted triazolinones |
US5281614A (en) * | 1991-05-10 | 1994-01-25 | Merck & Co., Inc. | Substituted 1,2,4-triazoles bearing acidic functional groups as angiotensin II antagonists |
US5411980A (en) * | 1989-07-28 | 1995-05-02 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
WO2000001389A1 (en) | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
WO2001044239A2 (en) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
US20040106833A1 (en) * | 1998-07-06 | 2004-06-03 | San Natesan Murug | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
WO2007109456A2 (en) * | 2006-03-16 | 2007-09-27 | Pharmacopeia, Inc. | Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists |
CN101891735A (zh) | 2009-11-25 | 2010-11-24 | 北京理工大学 | 联苯磺胺异噁唑类化合物、合成方法及用途 |
-
2022
- 2022-10-20 CN CN202280070467.6A patent/CN118119617A/zh active Pending
- 2022-10-20 CA CA3235437A patent/CA3235437A1/en active Pending
- 2022-10-20 WO PCT/CN2022/126482 patent/WO2023066348A1/zh active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411980A (en) * | 1989-07-28 | 1995-05-02 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
US5281614A (en) * | 1991-05-10 | 1994-01-25 | Merck & Co., Inc. | Substituted 1,2,4-triazoles bearing acidic functional groups as angiotensin II antagonists |
WO1993001177A1 (en) * | 1991-07-03 | 1993-01-21 | Merck & Co., Inc. | Substituted triazolinones |
WO2000001389A1 (en) | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
CN1308536A (zh) * | 1998-07-06 | 2001-08-15 | 布里斯托尔-迈尔斯斯奎布公司 | 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺 |
US20040106833A1 (en) * | 1998-07-06 | 2004-06-03 | San Natesan Murug | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
WO2001044239A2 (en) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
WO2007109456A2 (en) * | 2006-03-16 | 2007-09-27 | Pharmacopeia, Inc. | Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists |
CN101891735A (zh) | 2009-11-25 | 2010-11-24 | 北京理工大学 | 联苯磺胺异噁唑类化合物、合成方法及用途 |
Non-Patent Citations (1)
Title |
---|
"BQ123", AM J PHYSIOL, vol. 266, no. 2, April 1994 (1994-04-01), pages H1327 - 31 |
Also Published As
Publication number | Publication date |
---|---|
CN118119617A (zh) | 2024-05-31 |
CA3235437A1 (en) | 2023-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101715450B (zh) | 作为cftr调控剂的氮杂吲哚衍生物 | |
CN111566089B (zh) | Ire1小分子抑制剂 | |
JP2023075282A (ja) | オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 | |
WO2021190413A1 (zh) | 靶向降解黏着斑激酶的化合物及其在医药上的应用 | |
MXPA06004005A (es) | Moduladores de transportadores con casete de union con atp. | |
JP2021527690A (ja) | ピリジニル及びピラジニル−(アザ)インドールスルホンアミド | |
CN104918942A (zh) | 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途 | |
CN109422733A (zh) | 一类抑制并降解酪氨酸蛋白激酶alk的化合物 | |
JP6864379B2 (ja) | インドール類似体及びその使用 | |
JP2000503321A (ja) | 新規な融合ピロールカルボキサミド;新規な種類のgaba脳リセプタリガンド | |
EP1426046A1 (en) | Novel use of tricyclic compound | |
KR20110091550A (ko) | 5-ht2b 수용체 길항활성을 가지는 신규 피라졸-3-카복사미드 유도체 | |
TWI415613B (zh) | Anti-cancer agent resistance to overcome the agent | |
IL226790A (en) | Pyridonyl guanidine compounds inhibit f1f0 – atpase | |
WO2023066348A1 (zh) | 一种双重拮抗剂及其用途 | |
JP2017532377A (ja) | インドリノン化合物及びその使用 | |
CN108137514A (zh) | 芳基取代的二环杂芳基化合物 | |
WO2023030434A1 (zh) | 前列腺特异性膜抗原的抑制剂及其医药用途 | |
WO2023198066A1 (zh) | 氘代杂环酮类化合物及其用途 | |
WO2024008129A1 (zh) | 作为kat6抑制剂的化合物 | |
TW201408672A (zh) | □烷化合物 | |
KR20190066023A (ko) | 화합물, 상기 화합물을 얻기 위한 공정, 약제학적 조성물, 상기 화합물의 용도 및 정신 장애 및/또한 수면 장애를 치료하기 위한 방법 | |
WO2023125928A1 (zh) | Menin抑制剂及其用途 | |
Su et al. | Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis | |
CN110467616B (zh) | 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22882953 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3235437 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022882953 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022882953 Country of ref document: EP Effective date: 20240521 |